Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer

NCT00179686 is registered in ClinicalTrials.gov with Celgene Corporation as lead sponsor.

NCT NCT00179686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00179686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer
Lead sponsor
Celgene Corporation
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2005
Completion date
July 31, 2006
Enrollment
40
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer